Brind.

Investment Comparison of Quest Diagnostics and GeneDx Holdings Corp.

1 report, 1 independent Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A comparison of Quest Diagnostics and GeneDx Holdings Corp. reviewed several financial metrics, including revenue, earnings per share, and valuation. The review noted that GeneDx has a beta of 1.99, indicating higher volatility than the S&P 500, while Quest Diagnostics has a beta of 0.55, suggesting lower volatility. Analysts stated that GeneDx is more favorable based on its stronger consensus rating and higher probable upside, despite Quest Diagnostics having a higher percentage of shares held by institutional investors.

From dailypolitical.com

Why it matters

Some supportBrind's analysis of the reports

The comparison provides insight into the relative risk and growth potential of both healthcare companies. The differing volatility levels and analyst recommendations could influence investment decisions regarding the two firms.

From dailypolitical.com

Who's involved

  • Quest DiagnosticsMedical research company whose financial metrics and risk profile were compared against GeneDx Holdings Corp.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped